4th Jul 2019 12:37
(Alliance News) - SkinBioTherapeutics PLC on Thursday said its new chief executive has stepped into the role and the company is in advanced talks with partners over SkinBiotix.
Stuart Ashman was appointed CEO designate in March, having been CEO of Onbone Oy since 2014. Ashman succeeds prior CEO & Founder Cath O'Neill, who will become chief scientific officer and leave the company board. However, O'Neill is to become a member of SkinBioTherapeutics' newly established scientific advisory board.
In addition, Non-Executive Stephen O'Hara is leaving the life sciences company immediately given "his increasing commitments at OptiBiotix Health PLC".
The company announced the completion its first human study of SkinBiotix, its skincare product containing extracts from probiotic bacteria, in November 2018. The study found the product was safe and effective.
Now, SkinBioTherapeutics is involved in "advanced engagement with a number of potential partners" who have expressed interest in the technology and the study.
SkinBioTherapeutics Non-Executive CHair Martin Hunt said: "Following a recent strategic planning session with the executive team, it is clear that the company is now driving towards commercialisation with the skin product and has a broad and wide range of other opportunities available to it. The board is confident that, with Stuart as the new CEO and Cath as CSO, the company is in good hands for its next phase of development."
Shares in SkinBioTherapeutics were down 2.1% at 19.58 pence on Thursday at mid day.
Related Shares:
Skinbiotherap.